Semaglutide vs Tirzepatide

Semaglutide and tirzepatide are the two most widely prescribed incretin-based medications as of 2026, but they differ in mechanism of action and available formulations. Semaglutide is a GLP-1 receptor agonist marketed under three brand names: Ozempic (for type 2 diabetes), Wegovy (for chronic weight management), and Rybelsus (an oral tablet for type 2 diabetes). Tirzepatide is a dual GIP and GLP-1 receptor agonist available as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). The dual-receptor activity of tirzepatide distinguishes it as a different drug class from semaglutide, though both belong to the broader incretin therapy category.

Head-to-head data from the SURMOUNT-5 trial compared tirzepatide and semaglutide directly in adults with obesity or overweight. According to results presented at ObesityWeek 2024, tirzepatide demonstrated statistically superior weight loss compared to semaglutide at the maximum approved doses over 72 weeks. This trial is particularly significant because earlier comparisons relied on cross-trial data from separate study programs (STEP for semaglutide, SURMOUNT for tirzepatide), which carry inherent limitations due to differences in study populations and design. In those separate trials, semaglutide 2.4 mg showed approximately 14.9% weight reduction (STEP 1), while tirzepatide 15 mg showed approximately 22.5% (SURMOUNT-1).

Both active ingredients are available or in development across multiple formulations. Semaglutide is currently available in both injectable (Ozempic, Wegovy) and oral (Rybelsus) forms, with a higher-dose oral semaglutide formulation having completed late-stage clinical trials. Tirzepatide is currently available as an injection (Mounjaro, Zepbound), and an oral formulation of tirzepatide has shown positive results in clinical development. The gastrointestinal side-effect profile is broadly similar for both drugs, with nausea, vomiting, diarrhea, and constipation reported most commonly during dose titration, according to their respective FDA prescribing information.

Choosing between semaglutide and tirzepatide involves multiple factors beyond efficacy data alone, including the specific FDA-approved indication, available dosage forms, insurance formulary coverage, individual tolerability, and prescriber guidance. Both medications carry boxed warnings regarding thyroid C-cell tumors observed in rodent studies, and neither should be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Patients should consult their healthcare provider to determine which medication and formulation is most appropriate for their clinical situation.